PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Genomictree has entered a commercialization phase for its EarlyTect colon and bladder cancer early-detection tests at home and abroad, while still posting operating losses and negative operating cash flow.
Bladder cancer test EarlyTect-B began non-reimbursed prescriptions in Korea from August 2026, with expansion to general hospitals planned for Q4.
Colon cancer test EarlyTect-C is targeting a January 2027 national insurance reimbursement listing after a new health technology assessment.
In the US, subsidiary Promis Diagnostics operates an LDT service with a CPT-PLA code, while the follow-on EarlyTect-B Plus—granted FDA breakthrough device designation—is in clinical trial design discussions.
Full-year 2025 revenue recovered year over year, but large clinical trial spending kept the operating loss substantial, and the most recent four quarters do not yet reflect the effect of the August 2026 domestic non-reimbursed launch.
The debt ratio remains in the single digits, limiting balance-sheet risk, but owners' equity has shrunk each year as losses accumulate.
Genomictree is an in vitro molecular diagnostics company built on DNA methylation biomarker technology, with its core products being the colon cancer test EarlyTect-C and the bladder cancer test EarlyTect-B.
EarlyTect-C measures SDC2 methylation in stool samples and has been sold on a non-reimbursed basis since 2019 through domestic health-checkup centers and primary clinics, building a distribution network of more than 270 checkup centers and over 1,400 primary clinics.
EarlyTect-B analyzes PENK gene methylation from urine in a non-invasive format; after receiving final Korean regulatory approval and European CE-IVDR certification in January 2026, it gained an exemption from new health technology assessment that made non-reimbursed prescriptions possible in Korea starting in August 2026.
Overseas, the company has an exclusive distribution agreement with UK-based EDX Medical for its colon cancer test, secured contracts with the HCA and Spire hospital groups, and gained coverage under Bupa private insurance, while also pursuing entry for its bladder cancer test through major European diagnostics groups such as Synlab in Germany.
In the US market, it entered first through a Laboratory Developed Test service via subsidiary Promis Diagnostics and obtained a CPT-PLA code from the American Medical Association to establish a billing basis.
In Asia-Pacific, the company is working with DKSH to prioritize entry into Australia and New Zealand before expanding into Southeast Asia, and is collaborating with the Hanaro Medical Foundation's K-LAB in Indonesia.
Beyond diagnostics, the company has presented an mRNA delivery platform called LipoRnaX as a new growth driver, pursuing a mid- to long-term strategy of expanding its precision medicine value chain from diagnosis into treatment.
In the competitive landscape, Abbott of the US and Pacific Edge of New Zealand are cited as existing players in bladder cancer early detection, though a recent validity issue leading to a sales halt for a Pacific Edge product has raised the possibility of market realignment.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩1.7B | -₩1.5B | −87.5% |
| 2025Q3 | ₩900M | -₩3.4B | −384.0% |
| 2025Q4 | ₩800M | -₩2.6B | −317.5% |
| 2026Q1 | ₩400M | -₩3B | −793.9% |
| 2026Q2 | ₩800M | -₩2.6B | −313.9% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩29.9B | ₩2.4B | -₩6.6B | 8.1% | −6.2% | 51.5% |
| 2023 | ₩3.4B | -₩17.3B | -₩8.8B | −506.2% | −7.0% | 6.2% |
| 2024 | ₩2.4B | -₩15.3B | -₩10.2B | −648.2% | −8.3% | 5.1% |
| 2025 | ₩3.8B | -₩11.3B | -₩9B | −300.5% | −7.8% | 4.7% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-21
Genomictree's revenue plunged from 29.87 billion won in 2022 to 3.42 billion won in 2023, largely due to the disappearance of COVID-19 testing revenue from its US subsidiary, and operating profit flipped from a surplus of 2.41 billion won (an 8.1% margin) to a loss of 17.30 billion won (a -506.2% margin) over the same period.
Revenue declined further to 2.36 billion won in 2024 as the operating loss widened to 15.31 billion won, before recovering to 3.76 billion won in 2025, when the operating loss narrowed to 11.30 billion won.
Net loss attributable to owners widened from 8.76 billion won in 2023 to 10.24 billion won in 2024, then narrowed again to 8.99 billion won in 2025.
On a quarterly basis, the operating loss spiked to 3.44 billion won in the third quarter of 2025, which appears attributable to concentrated clinical trial spending, including EarlyTect-C's large-scale NEXT-CRC confirmatory study.
Revenue fell to 0.38 billion won in the first quarter of 2026, the lowest of the most recent five quarters, before rebounding to 0.84 billion won in the second quarter.
Notably, this trailing four-quarter window (Q3 2025 through Q2 2026) does not yet capture the effect of EarlyTect-B's domestic non-reimbursed prescriptions, which began in August 2026, so the commercialization impact will need to be confirmed in future quarterly results.
On the balance sheet, the debt ratio dropped sharply from 51.5% in 2022 to single digits (4.7%–6.2%) from 2023 onward, but owners' equity has declined each year, from 124.7 billion won in 2023 to 115.1 billion won in 2025, and operating cash flow was negative for three consecutive years from 2023 to 2025 (-10.88 billion, -13.63 billion, and -10.19 billion won, respectively), confirming ongoing cash consumption.
The in vitro molecular diagnostics industry is a growing field as demand rises for non-invasive tests that carry less pain and cost than invasive procedures such as biopsy or endoscopy, and the commercialization of methylation biomarker-based technology is spreading in early cancer detection for indications such as colon and bladder cancer.
In bladder cancer diagnostics, Genomictree competes with players such as Abbott in the US and Pacific Edge in New Zealand, and a recent validity issue that led to a sales halt for a Pacific Edge product has raised the possibility of a spillover benefit.
In Korea, the typical pathway is to enter the non-reimbursed market first via the new health technology assessment exemption system before moving toward reimbursement listing; EarlyTect-C took considerable time, from its 2018 approval to its 2023 non-reimbursed listing.
Drawing on that experience, the company achieved non-reimbursed market entry for EarlyTect-B within six months of approval.
In the US market, the LDT system allows for early commercialization ahead of full FDA approval, while the MolDx program for Medicare coverage runs in parallel, making the timing of fee-schedule determination and private insurer adoption a key variable for when results show up in revenue.
In Europe, the typical structure involves CE-IVDR-certified companies entering markets through partnerships with national diagnostics service groups, and Genomictree is likewise pursuing entry through partners such as EDX Medical in the UK and Synlab in Germany.
The company has laid out a plan to begin domestic commercialization of EarlyTect-B with non-reimbursed prescriptions at primary clinics starting in August, expand supply to secondary and tertiary hospitals in the fourth quarter via hospital test-code registration, pursue adoption into health checkup programs by year-end, and scale up checkup-center revenue from 2027.
For EarlyTect-C, the company applied for a new health technology assessment in March, with a Health Insurance Review and Assessment Service review running from June through December, targeting a reimbursement listing notice in January of the following year.
In the US, the EarlyTect-B follow-on product EarlyTect-B Plus, which received FDA breakthrough device designation, is under clinical trial design discussion, while the existing LDT service operates on the basis of collaboration and validation with the UCLA VA Medical Center, and a preliminary clinical laboratory fee schedule has already been determined by CMS.
In China, a roughly 1,000-subject confirmatory trial for EarlyTect-C is under way, with completion expected to be followed by a new health technology assessment application, though the company said the timing of the results announcement remains fluid.
Separately from its diagnostics business, the company is researching pan-RAS protein degradation and central nervous system and immune cell-targeted delivery technology through its mRNA delivery platform LipoRnaX at the proof-of-concept stage, and it has stated that commercialization will require considerable time.
Some in the securities industry view 2026 as a phase for confirming revenue growth, citing the start of EarlyTect-B's non-reimbursed sales and the emergence of overseas revenue for EarlyTect-C as grounds for that growth.
Genomictree has continued to post operating and net losses through the most recent four quarters, making earnings-based valuation comparisons difficult to derive in the first place.
From a price-to-book perspective, however, the stock trades in a range that reflects a certain premium over net asset value, which can be interpreted as partly incorporating expectations around EarlyTect-B's domestic and overseas commercialization progress and pipeline expansion.
With no dividend payment history in recent years, comparisons based on dividend yield carry limited significance.
The low debt ratio keeps balance-sheet risk itself limited, but owners' equity has declined each year and operating cash flow has remained negative, meaning the possibility of additional capital raising is a variable that needs to be weighed alongside any valuation assessment.
The basis for market evaluation may shift once the pace at which EarlyTect-B's domestic non-reimbursed revenue and overseas revenue actually flow into the financial statements becomes clearer.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-21
With EarlyTect-B's domestic non-reimbursed launch, EarlyTect-C's expansion into Europe and China, and the US LDT service all opening up simultaneously, the company is shifting toward a structure with lower dependence on any single region or product.
If each revenue source contributes at different points in time, this could also help smooth out revenue volatility.
The company describes EarlyTect-B as a urine-based PCR kit test with a standardized and automated workflow, a structure in which revenue could scale as test volume rises without proportional increases in headcount.
Having already secured multiple channels capable of processing large sample volumes, such as checkup centers, aligns with this structure.
Drawing on more than two decades of accumulated methylation research data, the company is developing the mRNA delivery platform LipoRnaX in an attempt to transition from a diagnostics company into a combined diagnostics-and-therapeutics platform company.
The proof-of-concept confirmation of pan-RAS protein degradation and central nervous system and immune cell-targeted delivery technology is cited as grounds for long-term pipeline diversification.
Operating cash flow was negative for three straight years from 2023 through 2025, and owners' equity has declined each year.
While revenue is recovering, the scale of the operating loss remains very large relative to revenue, and additional funding needs could continue until commercialization effects are fully reflected.
EarlyTect-C took a considerable amount of time from its 2018 approval to its 2023 non-reimbursed listing, and EarlyTect-B likewise saw its commercialization schedule pushed back due to an extended regulatory review and delays in the new health technology assessment exemption notice.
The targeted timing for EarlyTect-C's domestic reimbursement listing, January 2027, could also shift depending on how the review progresses.
Public awareness of bladder cancer testing is lower than that of colon cancer testing, and because the test is non-reimbursed, patients must bear the cost directly, which could slow the initial spread of demand.
Industry observers also note that securing a sales network does not necessarily translate directly into higher revenue.
EarlyTect-C's domestic reimbursement listing must pass through a Health Insurance Review and Assessment Service review from June to December 2026, and the targeted January 2027 notice could be pushed back depending on review delays or outcomes.
EarlyTect-B has a precedent of its new health technology assessment exemption notice being delayed beyond initial expectations, so a similar risk persists.
With operating cash flow negative for three straight years and owners' equity declining every year, additional capital raising could become necessary if commercialization effects are delayed. This is a variable that could affect the value of existing shareholders' stakes.
Multiple overseas processes are proceeding at the same time, including the formal FDA approval procedure and clinical trial design discussions in the US, the confirmatory trial and regulatory process in China, and contract execution with partners in Europe and Asia, raising the possibility that schedules could slip or partnerships might not be implemented as planned in some regions.
Third-quarter results should reveal how much of the effect from EarlyTect-B's August domestic non-reimbursed prescription launch has flowed into revenue.
This is the point to check progress on EarlyTect-B's hospital test-code registration, expanded supply to secondary and tertiary hospitals, and adoption into health checkup programs.
It will be important to confirm whether EarlyTect-C's Health Insurance Review and Assessment Service review is completed and whether the targeted January 2027 reimbursement listing notice remains achievable.
This is when it will be determined whether EarlyTect-C's domestic reimbursement listing notice is actually issued, requiring confirmation of both the notice itself and the reimbursement fee level.
It will be worth tracking together whether the FDA clinical trial design for EarlyTect-B Plus in the US is finalized and trial entry proceeds, as well as news of the completion of enrollment for EarlyTect-C's confirmatory trial in China.
Genomictree has entered a phase of simultaneously pursuing domestic commercialization of its colon and bladder cancer early-detection product line alongside overseas expansion into the US, Europe, and China; 2025 revenue recovered year over year, but the operating loss remained large due to substantial clinical trial spending.
The most recent four-quarter window (Q3 2025 through Q2 2026) does not yet include the effect of EarlyTect-B's August 2026 domestic non-reimbursed prescription launch, so the actual revenue contribution from commercialization will need to be confirmed in upcoming quarters.
On the balance sheet, a low debt ratio keeps near-term debt risk limited, but owners' equity has declined each year and operating cash flow has remained consistently negative, so the possibility of future capital raising also warrants attention.
EarlyTect-C's January 2027 reimbursement listing target, the pace of EarlyTect-B's expansion across domestic medical institutions, and the progress of regulatory procedures in the US and China stand out as key variables for gauging the direction of future results.
Bullish factors include the simultaneous expansion of multiple revenue sources across products and regions, operating leverage from a standardized test model, and the attempt to expand into a therapeutics platform, while bearish factors include ongoing losses and cash burn, a history of delays in reimbursement and administrative procedures, and low public awareness of bladder cancer testing.
Ahead of any investment judgment, it will be important to continue monitoring the pace at which revenue is reflected quarter by quarter and the progress of overseas regulatory procedures.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.